Literature DB >> 28537669

E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.

L Xie1, T Li, L-H Yang.   

Abstract

OBJECTIVE: To explore the genes co-upregulated with E2F2 in ovarian cancer and their association with survival outcomes in ovarian cancer patients.
MATERIALS AND METHODS: The raw data of GDS3592 was downloaded from GEO datasets for reanalysis. The overlapping subset between the top 150 upregulated genes in ovarian cancer epithelial cells (CEPIs) and the E2F2 positively correlated genes (Pearson's r≥0.5) in ovarian cancer cohort in TCGA was identified. The association between E2F2, MCM4, CCNE2 and WHSC1 and overall survival (OS) and recurrence-free survival (RFS) in ovarian cancer patients were assessed using Kaplan-Meier plotter.
RESULTS: E2F2 is a significantly upregulated transcription factor in CEPIs. MCM4, CCNE2, and WHSC1 are co-upregulated with E2F2 among the 308 ovarian cancer samples (Pearson's r=0.5159, 0.3963 and 0.4941 respectively). Enforced E2F2 expression significantly enhanced MCM4, CCNE2 and WHSC1 transcription in SKOV3 and A2780 cells. High E2F2 and CCNE2 expression are associated with worse OS (high E2F2, HR: 1.48, 95%CI: 1.17-1.85, p<0.01; high CCNE2, HR: 1.36, 95%CI: 1.15-1.6, p<0.01). High MCM expression might be associated with worse RFS at the margin of significance (HR: 1.18, 95%CI: 1.00-1.39, p=0.055).
CONCLUSIONS: MCM4, CCNE2, and WHSC1 are co-upregulated with E2F2 in ovarian cancer. Enforced E2F2 expression significantly increased MCM4, CCNE2, and WHSC1 expression in ovarian cancer cells. High E2F2 and CCNE2 expression are associated with worse OS among ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28537669

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  16 in total

1.  Overexpression of microRNA-936 suppresses non-small cell lung cancer cell proliferation and invasion via targeting E2F2.

Authors:  Xiao Zhou; Hui Tao
Journal:  Exp Ther Med       Date:  2018-07-20       Impact factor: 2.447

2.  Phase I trial of selenium plus chemotherapy in gynecologic cancers.

Authors:  Mihae Song; Muthu N Kumaran; Murugesan Gounder; Darlene G Gibbon; Wilberto Nieves-Neira; Ami Vaidya; Mira Hellmann; Michael P Kane; Brian Buckley; Weichung Shih; Paula B Caffrey; Gerald D Frenkel; Lorna Rodriguez-Rodriguez
Journal:  Gynecol Oncol       Date:  2018-07-29       Impact factor: 5.482

3.  Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer.

Authors:  Preethi Ravindranathan; Divya Pasham; Uthra Balaji; Jacob Cardenas; Jinghua Gu; Shusuke Toden; Ajay Goel
Journal:  Carcinogenesis       Date:  2018-05-28       Impact factor: 4.944

4.  miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.

Authors:  Qiu-Yan Lin; Jia-Qi Wang; Li-Li Wu; Wei-E Zheng; Pei-Rui Chen
Journal:  Breast Cancer       Date:  2019-08-13       Impact factor: 4.239

5.  High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study.

Authors:  Chuan Lan; Yo-Ichi Yamashita; Hiromitsu Hayashi; Shigeki Nakagawa; Katsunori Imai; Kosuke Mima; Takayoshi Kaida; Takashi Matsumoto; Masataka Maruno; Zhao Liu; Xiyu Wu; Feng Wei; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2022-04-13       Impact factor: 5.344

6.  Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma.

Authors:  Li-Peng Pei; Yun-Zheng Zhang; Guang-Ying Li; Jing-Li Sun
Journal:  Front Genet       Date:  2022-06-03       Impact factor: 4.772

7.  Prognostic roles of the expression of sphingosine-1-phosphate metabolism enzymes in non-small cell lung cancer.

Authors:  Yingqin Wang; Yaxing Shen; Xia Sun; Tinah L Hong; Long Shuang Huang; Ming Zhong
Journal:  Transl Lung Cancer Res       Date:  2019-10

8.  A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication.

Authors:  Yue Sheng; Jiangbo Wei; Fang Yu; Huanzhou Xu; Chunjie Yu; Qiong Wu; Yin Liu; Lei Li; Xiao-Long Cui; Xueying Gu; Bin Shen; Wei Li; Yong Huang; Sumita Bhaduri-McIntosh; Chuan He; Zhijian Qian
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

9.  LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma.

Authors:  Renbo Guo; Benkui Zou; Yiran Liang; Jiasheng Bian; Jian Xu; Qian Zhou; Chao Zhang; Tao Chen; Mingshan Yang; Huansheng Wang; Fajun Pei; Zhonghua Xu
Journal:  Cell Death Dis       Date:  2021-07-09       Impact factor: 8.469

10.  CARM1 promotes non-small cell lung cancer progression through upregulating CCNE2 expression.

Authors:  Deqin Wu; Jing He; Wei Zhang; Kai Wang; Shidai Jin; Jun Li; Wen Gao
Journal:  Aging (Albany NY)       Date:  2020-06-02       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.